·seekingalpha.comHigh
Harrow stock jumps as eye-care products deliver record Q3 sales
Harrow Health (HROW) reported Q3 GAAP EPS of $0.25, exceeding expectations. Shares rose 14% to $31.52, driven by record revenue and growth in eye-care products.
StockNASDAQ · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$HROW
HARROW, INC.
Harrow develops and markets ophthalmic pharmaceuticals and related disease-management therapies for eyecare professionals and patients, primarily in the U.S. and Canada. Its branded portfolio includes prescription and nonprescription eye drops, gels and injections for conditions such as dry eye, cataracts, retinal disease, inflammation, infection and allergic conjunctivitis. Harrow also develops drug candidates, including MELT-300, a sublingual tablet being developed for procedural sedation, and operates ImprimisRx, an ophthalmology-focused compounding business serving ophthalmologists, optometrists and their patients. Harrow makes money by marketing and selling branded medicines and compounded formulations. ImprimisRx dispenses patient-specific prescriptions through its 503A pharmacy and produces products for in-office use at its FDA-registered 503B outsourcing facility; its formulary includes over 30 compounded formulations. Harrow’s sales and marketing activities focus on educating doctors, surgery centers, healthcare systems, hospitals and other users about its products. It is headquartered in Nashville, Tennessee.
AlphAI earnings readsecond quarter 2026 · AUG 10Harrow reported second quarter 2026 revenue of $70.7 million, up 60% sequentially, and reiterated full-year 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA guidance of $80 million to $100 million.Verdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $HROWvia TradingView
AI sentiment · 7d7 articles
- Bullish
- 5
- Neutral
- 1
- Bearish
- 1
Insider · 30dAll trades →
No SEC Form 4 filings for $HROW in the last 30 days.
See all $HROW insider activity →Top stories · $HROWMore →
·investing.com
Harrow Q3 2026 slides: record revenue, product portfolio expansion
Harrow (HROW) reported Q3 2026 revenue of $99.3M, up 41% sequentially and 39% YoY, with adjusted EBITDA at $21.2M. Key products VEVYE, IHEEZO, and TRIESENCE drove growth. The company reaffirmed FY 2026 revenue guidance of $350M-$365M but lowered adjusted EBITDA outlook. Harrow expanded its product portfolio and commercial infrastructure, acquiring TYRVAYA in October 2026.
·SEC EDGAR 8-K
Harrow Announces Third Quarter 2026 Financial Results
HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Harrow Announces Third Quarter 2026 Financial Results Third Quarter 2026 and Selected Highlights: • Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year • Branded revenue of $83.5 million, up 62% year over year and approximately 84% of total r
HROW sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning HROW (HARROW, INC.). Coverage has skewed bullish: 5 bullish, 1 neutral, and 1 bearish.
Recent HROW coverage spans earnings, financial news and corporate actions.
What's driving HROW
Earnings beat and record eye‑care sales likely sustain upward momentum.
Shares surged on strong revenue and product growth, but lower EBITDA outlook may temper upside.
Strong revenue growth and reaffirmed guidance suggest upside potential.
The new platform adds a digital channel for Harrow's eye‑care products but no adoption metrics or revenue guidance were provided.
The deal adds a FDA‑approved product and a new prescriber base, likely boosting Harrow's revenue outlook.
AlphAI scores every news story that mentions HROW with an AI model for sentiment and relevance, and aggregates insider trades from HARROW, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $HROW
Score
Harrow stock jumps as eye-care products deliver record Q3 sales
Harrow Health (HROW) reported Q3 GAAP EPS of $0.25, exceeding expectations. Shares rose 14% to $31.52, driven by record revenue and growth in eye-care products.
Harrow Q3 2026 slides: record revenue, product portfolio expansion
Harrow (HROW) reported Q3 2026 revenue of $99.3M, up 41% sequentially and 39% YoY, with adjusted EBITDA at $21.2M. Key products VEVYE, IHEEZO, and TRIESENCE drove growth. The company reaffirmed FY 2026 revenue guidance of $350M-$365M but lowered adjusted EBITDA outlook. Harrow expanded its product portfolio and commercial infrastructure, acquiring TYRVAYA in October 2026.
Harrow Announces Third Quarter 2026 Financial Results
HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. Harrow Announces Third Quarter 2026 Financial Results Third Quarter 2026 and Selected Highlights: • Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year • Branded revenue of $83.5 million, up 62% year over year and approximately 84% of total r
Harrow, Inc. (HROW) Launches HarrowRx E-Prescribing Platform
Harrow, Inc. (HROW) launched HarrowRx, an e-prescribing and patient-access platform for its ophthalmic portfolio, including VEVYE. The platform is now available to eye care providers through connected EMR systems, extending its partnership with PHIL.
Harrow Closes Acquisition of TYRVAYA®
Harrow (HROW) completed its $30M acquisition of TYRVAYA nasal spray from Viatris, with up to $70M in milestone payments. TYRVAYA, approved for dry eye disease, complements Harrow's VEVYE product. Harrow expects $30M+ revenue from TYRVAYA in 2027, with 40 Viatris employees joining its team.
B. Riley’s Top Biotech Picks Ahead of 3Q26 Earnings Season
B. Riley analyst Mayank Mamtani highlighted top biotech picks ahead of 3Q26 earnings, including Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Eton Pharmaceuticals (ETON), Harrow (HROW), TG Therapeutics (TGTX), and Zymeworks (ZYME). The analyst provided price targets and revenue projections for each, noting macroeconomic challenges for small and mid-cap biotech stocks.
Harrow (HROW) Could Be 44% Undervalued After Accounting Leadership Change
Harrow (HROW) announced the departure of its Chief Accounting Officer, with the CFO taking over the role. The company's shares closed at $38.54, with mixed short-term momentum. Analysts suggest Harrow may be undervalued by 44%, citing strong growth potential in its ophthalmic drugs.
Harrow CFO Boll Adds Principal Accounting Officer Role After Pollard Exit – Minichart
Harrow, Inc. (HROW) announced Randall E. Pollard's departure as Chief Accounting Officer. Andrew R. Boll, the CFO, will also serve as principal accounting officer without additional compensation. No reason was given for Pollard's exit.
HARROW, INC. (HROW): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
HARROW, INC. (HROW) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective September 4, 2026, Randall E. Pollard ceased serving as Chief Accounting Officer and principal accounting officer
Harrow (HROW) Reported Positive IHEEZO Study Results In Intravitreal Injections
Harrow (HROW) announced positive clinical study results for its IHEEZO ophthalmic gel, showing reduced patient discomfort during intravitreal injections. The study is relevant for Harrow's focus on specialty eye care and may impact its revenue mix. Investors will watch for real-world adoption in retina practices.